{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:01:46Z","timestamp":1793826106762,"version":"4.6.1"},"reference-count":222,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":811,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.cmi.2021.09.036","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T05:21:38Z","timestamp":1637126498000},"page":"163-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":193,"title":["Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review"],"prefix":"10.1016","volume":"28","author":[{"given":"Simon","family":"Galmiche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liem Binh","family":"Luong Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Tartour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"de Lamballerie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Wittkop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Loubet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odile","family":"Launay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2021.09.036_bib1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ijc.33213","article-title":"Cancer associates with risk and severe events of COVID-19: a systematic review and meta-analysis","volume":"148","author":"Tian","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cmi.2021.09.036_bib2","doi-asserted-by":"crossref","first-page":"100588","DOI":"10.1016\/j.trre.2020.100588","article-title":"COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis of current literature","volume":"35","author":"Raja","year":"2021","journal-title":"Transplant Rev Orlando Fla"},{"key":"10.1016\/j.cmi.2021.09.036_bib3","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/ajt.16424","article-title":"Is COVID-19 infection more severe in kidney transplant recipients?","volume":"21","author":"Caillard","year":"2021","journal-title":"Am J Transplant Surg"},{"key":"10.1016\/j.cmi.2021.09.036_bib4","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.kint.2020.07.042","article-title":"Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients","volume":"98","author":"Couchoud","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.cmi.2021.09.036_bib5","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1093\/ndt\/gfaa261","article-title":"COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration","volume":"35","author":"Hilbrands","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cmi.2021.09.036_bib6","first-page":"527","article-title":"FAI2R\/SFR\/SNFMI\/SOFREMIP\/CRI\/IMIDIATE consortium and contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients","volume":"80","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2021.09.036_bib7","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.2215\/CJN.02160311","article-title":"Efficacy of influenza A H1N1\/2009 vaccine in hemodialysis and kidney transplant patients","volume":"6","author":"Crespo","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cmi.2021.09.036_bib8","doi-asserted-by":"crossref","first-page":"e661","DOI":"10.1093\/cid\/ciaa1897","article-title":"Immunogenicity and safety of the nine-valent human papillomavirus vaccine in solid organ transplant recipients and HIV-infected adults","volume":"73","author":"Boey","year":"2021","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.cmi.2021.09.036_bib9","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1200\/JCO.19.00354","article-title":"Influenza vaccine effectiveness among patients with cancer: a population-based study using health administrative and laboratory testing Data from Ontario, Canada","volume":"37","author":"Blanchette","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2021.09.036_bib10","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/21645515.2016.1246094","article-title":"Immunogenicity of trivalent influenza vaccine in patients with lung cancer undergoing anticancer chemotherapy","volume":"13","author":"Nakashima","year":"2017","journal-title":"Hum Vaccine Immunother"},{"key":"10.1016\/j.cmi.2021.09.036_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001035","article-title":"Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations","volume":"5","author":"Rondaan","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.cmi.2021.09.036_bib15","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1093\/ckj\/sfab109","article-title":"Humoral response after BNT162b2 mRNA COVID-19 vaccination in patients on haemodialysis depends on immune status","volume":"14","author":"Ducloux","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.cmi.2021.09.036_bib16","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.kint.2021.06.025","article-title":"Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis","volume":"100","author":"Ducloux","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.cmi.2021.09.036_bib17","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.kint.2021.07.005","article-title":"The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis","volume":"100","author":"Espi","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.cmi.2021.09.036_bib18","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1097\/TP.0000000000003863","article-title":"Antibody kinetics and durability in SARS-CoV-2 mRNA vaccinated solid organ transplant recipients","volume":"105","author":"Boyarsky","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2021.09.036_bib19","article-title":"Justification, safety, and efficacy of a third dose of mRNA vaccine in maintenance hemodialysis patients: a prospective observational study","author":"Espi","year":"2021","journal-title":"MedRxiv"},{"key":"10.1016\/j.cmi.2021.09.036_bib20","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1001\/jama.2021.7489","article-title":"Antibody response to 2-dose SARS-COV-2 mRNA vaccine series in solid organ transplant recipients","volume":"325","author":"Boyarsky","year":"2021","journal-title":"JAMA - J Am Med Assoc"},{"key":"10.1016\/j.cmi.2021.09.036_bib21","doi-asserted-by":"crossref","first-page":"100178","DOI":"10.1016\/j.lanepe.2021.100178","article-title":"Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: a prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine","volume":"9","author":"Stumpf","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.cmi.2021.09.036_bib22","doi-asserted-by":"crossref","DOI":"10.1097\/TP.0000000000003903","article-title":"Cellular and humoral immune responses after three doses of BNT162b2 mRNA SARS-Cov-2 vaccine in kidney transplant","author":"Stumpf","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2021.09.036_bib23","article-title":"Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients","author":"Del Bello","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2021.09.036_bib24","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1056\/NEJMc2108861","article-title":"Three Doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients","volume":"385","author":"Kamar","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2021.09.036_bib25","doi-asserted-by":"crossref","DOI":"10.1097\/TP.0000000000003934","article-title":"Antibody response to a fourth dose of a SARS-CoV-2 vaccine in solid organ transplant recipients: a case series","author":"Alejo","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2021.09.036_bib26","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.7326\/L21-0282","article-title":"Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series","volume":"174","author":"Werbel","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2021.09.036_bib27","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1136\/annrheumdis-2021-221145","article-title":"Antibody response to the Janssen\/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases","volume":"80","author":"Chiang","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2021.09.036_bib28","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/annrheumdis-2021-220656","article-title":"High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases","volume":"80","author":"Ruddy","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2021.09.036_bib29","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1097\/TP.0000000000003850","article-title":"Antibody response to the Janssen COVID-19 vaccine in solid organ transplant recipients","volume":"105","author":"Boyarsky","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2021.09.036_bib30","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ccell.2021.06.002","article-title":"Seroconversion rates following COVID-19 vaccination among patients with cancer","volume":"39","author":"Thakkar","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cmi.2021.09.036_bib31","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1681\/ASN.2021050611","article-title":"Antibody response to COVID-19 vaccination in patients receiving dialysis","volume":"32","author":"Anand","year":"2021","journal-title":"J\u00a0Am Soc Nephrol JASN"},{"key":"10.1016\/j.cmi.2021.09.036_bib32","article-title":"Antibody responses to SARS-CoV-2 after infection or vaccination in children and young adults with inflammatory bowel disease","author":"Dailey","year":"2021","journal-title":"MedRxiv"},{"key":"10.1016\/j.cmi.2021.09.036_bib33","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.2021012443","article-title":"Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell directed therapies","volume":"138","author":"Ghione","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2021.09.036_bib34","article-title":"Vaccine serologic responses among transplant patients associate with COVID-19 infection and T peripheral helper cells","author":"Lemieux","year":"2021","journal-title":"MedRxiv"},{"key":"10.1016\/j.cmi.2021.09.036_bib35","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1182\/blood.2021012769","article-title":"Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR-T cell therapy","volume":"138","author":"Dhakal","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2021.09.036_bib36","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1136\/annrheumdis-2021-220972","article-title":"Correspondence on \u201cSARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response\u201d by Bonelli et al","volume":"80","author":"Connolly","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2021.09.036_bib37","article-title":"Evaluation of immune response and disease status in SLE patients following SARS-CoV-2 vaccination","author":"Izmirly","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.cmi.2021.09.036_bib38","article-title":"COVID19 vaccine type and humoral immune response in patients receiving dialysis","author":"Garcia","year":"2021","journal-title":"MedRxiv Preprint Serv Health Sci"},{"key":"10.1016\/j.cmi.2021.09.036_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izab194","article-title":"Seroconversion following SARS-CoV-2 infection or vaccination in pediatric IBD patients","author":"Spencer","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cmi.2021.09.036_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2021.08.008","article-title":"Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases","author":"Thuluvath","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2021.09.036_bib41","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2352-3018(21)00103-X","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2\/3 clinical trial","volume":"8","author":"Frater","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cmi.2021.09.036_bib42","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S2352-3026(21)00199-X","article-title":"Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma","volume":"8","author":"Lim","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.cmi.2021.09.036_bib43","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41408-021-00528-x","article-title":"Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia","volume":"11","author":"Parry","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.cmi.2021.09.036_bib44","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.ekir.2021.07.009","article-title":"Neutralizing SARS-CoV-2 antibody response and protective effect of two doses of ChAdOx1 nCoV-19 and BBV152 vaccines in hemodialysis patients \u2013 preliminary report","volume":"6","author":"Fernando","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.cmi.2021.09.036_bib45","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/annrheumdis-2021-220626","article-title":"Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression","volume":"80","author":"Prendecki","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2021.09.036_bib46","article-title":"T cell response after SARS-CoV-2 vaccination in immunocompromised patients with inflammatory bowel disease","author":"Reuken","year":"2021","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cmi.2021.09.036_bib47","article-title":"Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies","author":"Boekel","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.cmi.2021.09.036_bib48","doi-asserted-by":"crossref","first-page":"E568","DOI":"10.1016\/S2352-3018(21)00157-0","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B\/2A trial","volume":"8","author":"Madhi","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cmi.2021.09.036_bib49","first-page":"2210","article-title":"Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients","author":"Heudel","year":"2021","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.cmi.2021.09.036_bib50","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00296-021-04910-7","article-title":"Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly","volume":"41","author":"Seyahi","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.cmi.2021.09.036_bib51","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1038\/s41591-021-01469-5","article-title":"Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial","volume":"27","author":"Medeiros-Ribeiro","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2021.09.036_bib52","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2021-0597","article-title":"Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy","author":"Karacin","year":"2021","journal-title":"Future Oncol Lond Engl"},{"key":"10.1016\/j.cmi.2021.09.036_bib53","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa2103055","article-title":"Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant","volume":"384","author":"Shinde","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2021.09.036_bib54","doi-asserted-by":"crossref","first-page":"103150","DOI":"10.1016\/j.msard.2021.103150","article-title":"Humoral response to SARS-CoV-2 and COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies","volume":"54","author":"Drulovic","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.cmi.2021.09.036_bib55","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/annrheumdis-2021-220597","article-title":"Methotrexate hampers immunogenicity to BNT162B2 mRNA covid-19 vaccine in immune-mediated inflammatory disease","volume":"80","author":"Haberman","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2021.09.036_bib56","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1111\/ajt.16701","article-title":"Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients","volume":"21","author":"Cucchiari","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2021.09.036_bib57","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1111\/ajt.16702","article-title":"Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients","volume":"21","author":"Miele","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2021.09.036_bib58","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1097\/TP.0000000000003784","article-title":"Poor Anti-SARS-CoV-2 humoral and T-cell responses after 2 injections of mRNA vaccine in kidney transplant recipients treated with belatacept","volume":"105","author":"Chavarot","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2021.09.036_bib59","article-title":"Immune responses to COVID-19 mRNA vaccines in patients with solid tumors on active, immunosuppressive cancer therapy","author":"Shroff","year":"2021","journal-title":"MedRxiv Preprint Serv Health Sci"},{"key":"10.1016\/j.cmi.2021.09.036_bib60","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2021.09.036_bib61","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jaci.2021.05.029","article-title":"Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity","volume":"148","author":"Hagin","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.cmi.2021.09.036_bib62","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1681\/ASN.2021040480","article-title":"Antibody and T cell response to SARS-CoV-2 messenger RNA BNT162b2 vaccine in kidney transplant recipients and hemodialysis patients","volume":"32","author":"Bertrand","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.cmi.2021.09.036_bib63","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150175","article-title":"Impaired humoral and cellular immunity after SARS-CoV2 BNT162b2 (Tozinameran) prime-boost vaccination in kidney transplant recipients","volume":"131","author":"Sattler","year":"2021","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cmi.2021.09.036_bib64","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1053\/j.ajkd.2021.06.002","article-title":"Humoral and cellular responses to mRNA-1273 and BNT162b2 SARS-CoV-2 vaccines administered to hemodialysis patients","volume":"78","author":"Broseta","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cmi.2021.09.036_bib65","doi-asserted-by":"crossref","DOI":"10.1111\/joim.13361","article-title":"Immunogenicity of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients","author":"Holden","year":"2021","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.cmi.2021.09.036_bib66","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1007\/s00392-021-01880-5","article-title":"Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients","volume":"110","author":"Schramm","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.cmi.2021.09.036_bib67","article-title":"The BNT162b2 mRNA vaccine elicits robust humoral and cellular immune responses in people living with HIV","author":"Woldemeskel","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.09.036_bib68","first-page":"423","article-title":"Immunogenicity and safety of the BNT162b2 mRNA Covid-19 vaccine in people living with HIV-1","author":"Levy","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2021.09.036_bib69","doi-asserted-by":"crossref","DOI":"10.1097\/TP.0000000000003889","article-title":"Humoral response of renal transplant recipients to the BNT162b2 SARS-CoV-2 mRNA vaccine using both RBD IgG and neutralizing antibodies","author":"Hod","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2021.09.036_bib70","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2021.279196","article-title":"Safety and efficacy of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia","author":"Benjamini","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2021.09.036_bib71","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41408-021-00530-3","article-title":"The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.cmi.2021.09.036_bib72","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.16766","article-title":"Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients","author":"Hall","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2021.09.036_bib73","doi-asserted-by":"crossref","DOI":"10.1093\/clinchem\/hvab149","article-title":"Poor humoral response in solid organ transplant recipients following complete mRNA SARS-CoV-2 vaccination","author":"Cao","year":"2021","journal-title":"Clin Chem"},{"key":"10.1016\/j.cmi.2021.09.036_bib74","doi-asserted-by":"crossref","first-page":"103524","DOI":"10.1016\/j.ebiom.2021.103524","article-title":"Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis","volume":"70","author":"Strengert","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.cmi.2021.09.036_bib75","series-title":"Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients","author":"Massa","year":"2021"},{"key":"10.1016\/j.cmi.2021.09.036_bib76","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41408-021-00534-z","article-title":"Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies","volume":"11","author":"Malard","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.cmi.2021.09.036_bib77","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1056\/NEJMc2111462","article-title":"Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients","volume":"385","author":"Hall","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2021.09.036_bib78","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.kint.2021.07.002","article-title":"Neutralizing antibody response against variants of concern after vaccination of dialysis patients with BNT162b2","volume":"100","author":"Speer","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.cmi.2021.09.036_bib79","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.16818","article-title":"Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients","author":"Schmidt","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2021.09.036_bib80","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.kint.2021.07.006","article-title":"Superior cellular and humoral immunity toward SARS-CoV-2 reference and alpha and beta VOC strains in COVID-19 convalescent as compared to the prime boost BNT162b2-vaccinated dialysis patients","volume":"100","author":"Blazquez-Navarro","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.cmi.2021.09.036_bib81","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.16768","article-title":"Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients","author":"Herrera","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2021.09.036_bib82","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s12026-021-09212-5","article-title":"Presence of specific T cell response after SARS-CoV-2 vaccination in rheumatoid arthritis patients receiving rituximab","volume":"69","author":"Benucci","year":"2021","journal-title":"Immunol Res"},{"key":"10.1016\/j.cmi.2021.09.036_bib83","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.ccell.2021.07.016","article-title":"Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer","volume":"39","author":"Ehmsen","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cmi.2021.09.036_bib84","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jtct.2021.06.024","article-title":"Safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients after allogeneic HCT or CD19-based CART therapy-A single-center prospective cohort study","volume":"27","author":"Ram","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.cmi.2021.09.036_bib85","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1016\/S2352-3026(21)00169-1","article-title":"Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study","volume":"8","author":"Maneikis","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.cmi.2021.09.036_bib86","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ajh.26284","article-title":"BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies","volume":"96","author":"Tzarfati","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cmi.2021.09.036_bib87","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ejca.2021.05.036","article-title":"High levels of anti-SARS-CoV-2 IgG antibodies in previously infected patients with cancer after a single dose of BNT 162b2 vaccine","volume":"154","author":"Fong","year":"2021","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.cmi.2021.09.036_bib88","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bjh.17608","article-title":"Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma","volume":"195","author":"Avivi","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cmi.2021.09.036_bib89","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2021.09.036_bib90","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.ccell.2021.06.009","article-title":"Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer","volume":"39","author":"Addeo","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cmi.2021.09.036_bib91","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jamaoncol.2021.2155","article-title":"Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer","volume":"7","author":"Massarweh","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cmi.2021.09.036_bib92","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-021-01090-6","article-title":"Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution","volume":"14","author":"Pimpinelli","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.cmi.2021.09.036_bib93","article-title":"Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients","author":"Agha","year":"2021","journal-title":"MedRxiv Preprint Serv Health Sci"},{"key":"10.1016\/j.cmi.2021.09.036_bib94","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1007\/s00259-021-05389-x","article-title":"Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy","volume":"48","author":"Cohen","year":"2021","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.cmi.2021.09.036_bib95","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1038\/s41375-020-01030-2","article-title":"Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia","volume":"34","author":"Roeker","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.cmi.2021.09.036_bib96","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.annonc.2021.04.019","article-title":"Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors","volume":"32","author":"Barri\u00e8re","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cmi.2021.09.036_bib97","first-page":"136","article-title":"Serological response to COVID-19 vaccination in patients with cancer older than 80 years","author":"Iacono","year":"2021","journal-title":"J\u00a0Geriatr Oncol"},{"key":"10.1016\/j.cmi.2021.09.036_bib98","article-title":"Impaired humoral immunity to SARS-CoV-2 vaccination in non-Hodgkin lymphoma and CLL patients","author":"Diefenbach","year":"2021","journal-title":"MedRxiv"},{"key":"10.1016\/j.cmi.2021.09.036_bib99","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejca.2021.06.002","article-title":"The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: a monocentric experience","volume":"154","author":"Revon-Riviere","year":"2021","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.cmi.2021.09.036_bib100","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2021.279216","article-title":"Humoral serologic response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies","author":"Gurion","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2021.09.036_bib101","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13045-021-01130-1","article-title":"Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia","volume":"14","author":"Pimpinelli","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.cmi.2021.09.036_bib102","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(21)01594-4","article-title":"Antibody response after second BNT162b2 dose in allogeneic HSCT recipients","volume":"398","author":"Redjoul","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.cmi.2021.09.036_bib103","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ccell.2021.07.012","article-title":"Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cmi.2021.09.036_bib104","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ccell.2021.06.014","article-title":"Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma","volume":"39","author":"Van Oekelen","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cmi.2021.09.036_bib105","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.17743","article-title":"Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients","author":"Benda","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cmi.2021.09.036_bib106","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/bloodadvances.2021005094","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma","volume":"5","author":"Perry","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.cmi.2021.09.036_bib107","doi-asserted-by":"crossref","first-page":"E410","DOI":"10.1002\/ajh.26322","article-title":"Serologic response to mRNA COVID-19 vaccination in lymphoma patients","volume":"96","author":"Jurgens","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cmi.2021.09.036_bib108","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-021-01354-7","article-title":"Response to mRNA vaccination for COVID-19 among patients with multiple myeloma","author":"Stampfer","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.cmi.2021.09.036_bib109","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1038\/s41375-021-01380-5","article-title":"Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia","volume":"35","author":"Tadmor","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.cmi.2021.09.036_bib110","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.3390\/cancers13164191","article-title":"Efficacy of the mRNA-based BNT162b2 COVID-19 vaccine in patients with solid malignancies treated with anti-neoplastic drugs","volume":"13","author":"Agbarya","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.cmi.2021.09.036_bib111","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/bloodadvances.2021005328","article-title":"Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies","volume":"5","author":"Crombie","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.cmi.2021.09.036_bib112","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine among actively treated cancer patients","author":"Ligumsky","year":"2021","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cmi.2021.09.036_bib113","first-page":"1","article-title":"Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies","author":"Re","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cmi.2021.09.036_bib114","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/ndt\/gfab165","article-title":"Efficacy of the BNT162b2 mRNA covid-19 vaccine in a hemodialysis cohort","volume":"36","author":"Frantzen","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cmi.2021.09.036_bib115","article-title":"Immunogenicity of SARS-CoV-2 vaccine in dialysis","author":"Lacson","year":"2021","journal-title":"MedRxiv"},{"key":"10.1016\/j.cmi.2021.09.036_bib116","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.kint.2021.04.006","article-title":"Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients","volume":"99","author":"Yanay","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.cmi.2021.09.036_bib117","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/ndt\/gfab155","article-title":"Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients - a prospective cohort study","volume":"36","author":"Agur","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cmi.2021.09.036_bib118","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/ndt\/gfab179","article-title":"Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared to healthy controls","volume":"36","author":"Simon","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cmi.2021.09.036_bib119","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/ndt\/gfab195","article-title":"Weekly seroconversion rate of the mRNA-1273 SARS-CoV-2 vaccine in hemodialysis patients","volume":"36","author":"JJB","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cmi.2021.09.036_bib120","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1681\/ASN.2021040490","article-title":"Humoral response after SARS-Cov-2 mRNA vaccine in a cohort of hemodialysis patients and kidney transplant recipients","volume":"32","author":"Danthu","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.cmi.2021.09.036_bib121","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/vaccines9040360","article-title":"Humoral response to SARS-CoV-2-vaccination with BNT162b2 (Pfizer BioNTech) in patients on hemodialysis","volume":"9","author":"Jahn","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.cmi.2021.09.036_bib122","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.kint.2021.04.009","article-title":"Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients","volume":"99","author":"Attias","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.cmi.2021.09.036_bib123","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.2215\/CJN.04080321","article-title":"Antibody response to mRNA-1273 SARS-CoV-2 vaccine in hemodialysis patients with and without prior COVID-19","volume":"16","author":"Chan","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cmi.2021.09.036_bib124","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.2215\/CJN.03500321","article-title":"Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis","volume":"16","author":"Grupper","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cmi.2021.09.036_bib125","doi-asserted-by":"crossref","first-page":"704773","DOI":"10.3389\/fimmu.2021.704773","article-title":"The safety and immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 vaccine in hemodialysis patients","volume":"12","author":"Zitt","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2021.09.036_bib126","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abj1031","article-title":"Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients","volume":"6","author":"Rincon-Arevalo","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.cmi.2021.09.036_bib127","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.kint.2021.05.018","article-title":"Humoral response of mRNA-1273 SARS-CoV-2 vaccine in peritoneal dialysis patients","volume":"100","author":"Rodr\u00edguez-Espinosa","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.cmi.2021.09.036_bib128","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2215\/CJN.03700321","article-title":"Early humoral responses of hemodialysis patients after COVID-19 vaccination with BNT162b2","volume":"16","author":"Speer","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cmi.2021.09.036_bib129","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1093\/ndt\/gfab193","article-title":"High immunogenicity of a messenger RNA based vaccine against SARS-CoV-2 in chronic dialysis patients","volume":"36","author":"Longlune","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cmi.2021.09.036_bib130","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.kint.2021.07.004","article-title":"Comparison of BNT162b2 (Pfizer-BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients","volume":"100","author":"Kaiser","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.cmi.2021.09.036_bib131","doi-asserted-by":"crossref","first-page":"690698","DOI":"10.3389\/fimmu.2021.690698","article-title":"Immunogenicity of COVID-19 tozinameran vaccination in patients on chronic dialysis","volume":"12","author":"Schrezenmeier","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2021.09.036_bib132","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/hdi.12972","article-title":"Successful COVID-19 vaccination for patients on dialysis in Vilnius County","volume":"25","author":"Ivanauskaite","year":"2021","journal-title":"Hemodial Int"},{"key":"10.1016\/j.cmi.2021.09.036_bib133","first-page":"797","article-title":"Humoral response to SARS-CoV-2 vaccination promises to improve the catastrophic prognosis of hemodialysis patients as a result of COVID-19. The COViNEPH Project","volume":"131","author":"Tylicki","year":"2021","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.cmi.2021.09.036_bib134","first-page":"774","article-title":"Immunogenicity of BNT162b2 SARS-CoV-2 vaccine in a multicenter cohort of nursing home residents receiving maintenance hemodialysis","author":"Labriola","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cmi.2021.09.036_bib136","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1097\/TP.0000000000003824","article-title":"Immunogenicity and reactogenicity after SARS-CoV-2 mRNA vaccination in kidney transplant recipients taking belatacept","volume":"105","author":"Ou","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2021.09.036_bib137","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.7326\/M21-1341","article-title":"Safety and immunogenicity of anti-SARS-CoV-2 messenger RNA vaccines in recipients of solid organ transplants","volume":"174","author":"Marion","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2021.09.036_bib138","first-page":"1173","article-title":"Antibody response to mRNA SARS-CoV-2 vaccine among kidney transplant recipients \u2013 prospective cohort study","volume":"27","author":"Rozen-Zvi","year":"2021","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2021.09.036_bib139","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.kint.2021.04.005","article-title":"Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine","volume":"99","author":"Benotmane","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.cmi.2021.09.036_bib140","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2213-2600(21)00184-3","article-title":"Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine","volume":"9","author":"Shostak","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2021.09.036_bib141","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1097\/TP.0000000000003856","article-title":"Low immunization rate in kidney transplant recipients also after dose 2 of the BNT162b2 vaccine: continue to keep your guard up","volume":"105","author":"Midtvedt","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2021.09.036_bib142","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1111\/ajt.16615","article-title":"Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus","volume":"21","author":"Grupper","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2021.09.036_bib143","article-title":"Poor Antibody response after two doses of SARS-CoV-2 vaccine in transplant recipients","author":"Mazzola","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.09.036_bib144","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jhep.2021.04.020","article-title":"Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients","volume":"75","author":"Rabinowich","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2021.09.036_bib145","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.healun.2021.04.003","article-title":"BNT162b2 vaccination in heart transplant recipients: clinical experience and antibody response","volume":"40","author":"Peled","year":"2021","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.cmi.2021.09.036_bib146","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3390\/vaccines9070708","article-title":"Serological response in lung transplant recipients after two doses of SARS-CoV-2 mRNA vaccines","volume":"9","author":"Narasimhan","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.cmi.2021.09.036_bib147","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/ejhf.2199","article-title":"Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients \u2013 a prospective cohort study","volume":"23","author":"Itzhaki Ben Zadok","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cmi.2021.09.036_bib148","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1111\/ajt.16607","article-title":"Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients","volume":"21","author":"Marinaki","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2021.09.036_bib149","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.healun.2021.05.004","article-title":"Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients","volume":"40","author":"Havlin","year":"2021","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.cmi.2021.09.036_bib150","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.ekir.2021.04.017","article-title":"Post-vaccine anti-SARS-CoV-2 spike protein antibody development in kidney transplants recipients","volume":"6","author":"Husain","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.cmi.2021.09.036_bib151","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3390\/v13050756","article-title":"Impaired humoral response in renal transplant recipients to SARS-CoV-2 vaccination with BNT162b2 (Pfizer-BioNTech)","volume":"13","author":"Korth","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.cmi.2021.09.036_bib152","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.16726","article-title":"Serological response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients depends on prior exposure to SARS-CoV-2","author":"Firket","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2021.09.036_bib153","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jama.2021.12339","article-title":"Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses","volume":"326","author":"Benotmane","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2021.09.036_bib154","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/vaccines9070738","article-title":"Humoral response to SARS-Cov-2 vaccination in liver transplant recipients-a single-center experience","volume":"9","author":"Rashidi-Alavijeh","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.cmi.2021.09.036_bib155","first-page":"1961","article-title":"Effectiveness of SARS-Cov-2 vaccination in liver transplanted patients: the debate is open","author":"Guarino","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2021.09.036_bib156","doi-asserted-by":"crossref","DOI":"10.1097\/TP.0000000000003922","article-title":"Serological response to the BNT162b2 COVID-19 mRNA vaccine in adolescent and young adult kidney transplant recipients","author":"Haskin","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2021.09.036_bib157","doi-asserted-by":"crossref","DOI":"10.1097\/TP.0000000000003923","article-title":"Immune response post-SARS-CoV-2 mRNA vaccination in kidney-transplant recipients receiving belatacept","author":"Noble","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2021.09.036_bib158","article-title":"Disappointing immunization rate after 2 doses of the BNT162b2 vaccine in a Belgian cohort of kidney transplant recipients","author":"Georgery","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2021.09.036_bib159","doi-asserted-by":"crossref","DOI":"10.1002\/lt.26273","article-title":"Antibody response to SARS-CoV-2 messenger RNA vaccines in liver transplant recipients","author":"Strauss","year":"2021","journal-title":"Liver Transplant"},{"key":"10.1016\/j.cmi.2021.09.036_bib160","first-page":"2445","article-title":"SARS-CoV-2 messenger RNA vaccine antibody response and reactogenicity in heart and lung transplant recipients","author":"Hallett","year":"2021","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.cmi.2021.09.036_bib161","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2021.09.036_bib162","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1136\/annrheumdis-2021-220503","article-title":"Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2","volume":"80","author":"Braun-Moscovici","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2021.09.036_bib163","article-title":"Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2","author":"Deepak","year":"2021","journal-title":"MedRxiv"},{"key":"10.1016\/j.cmi.2021.09.036_bib164","article-title":"Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies","volume":"14","author":"Achiron","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.cmi.2021.09.036_bib165","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1136\/annrheumdis-2021-220604","article-title":"Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases","volume":"80","author":"Spiera","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2021.09.036_bib166","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/annrheumdis-2021-220461","article-title":"SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases","volume":"80","author":"Simon","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2021.09.036_bib167","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/S2665-9913(21)00186-7","article-title":"Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis","volume":"3","author":"Rubbert-Roth","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.cmi.2021.09.036_bib168","article-title":"Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience","author":"Guerrieri","year":"2021","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.cmi.2021.09.036_bib169","first-page":"569","article-title":"Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: a mirror of the response after SARS-CoV-2 infection","author":"Bigaut","year":"2021","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.cmi.2021.09.036_bib170","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1136\/gutjnl-2021-324789","article-title":"Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD","volume":"70","author":"Kennedy","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.cmi.2021.09.036_bib171","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2021.04.025","article-title":"Serologic response to messenger RNA coronavirus disease 2019 vaccines in inflammatory bowel disease patients receiving biologic therapies","volume":"161","author":"Wong","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmi.2021.09.036_bib172","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1136\/annrheumdis-2021-220272","article-title":"Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort","volume":"80","author":"Geisen","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2021.09.036_bib173","article-title":"Efficacy and safety of SARS-CoV-2 vaccine in patients with giant cell arteritis","author":"Callejas Rubio","year":"2021","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.cmi.2021.09.036_bib174","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1136\/annrheumdis-2021-220898","article-title":"Correspondence on \u201cImmunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort","volume":"80","author":"Valor-M\u00e9ndez","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2021.09.036_bib175","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/acr2.11299","article-title":"Impaired antibody response to the BNT162b2 messenger RNA coronavirus disease 2019 vaccine in patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"3","author":"Ammitzb\u00f8ll","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.cmi.2021.09.036_bib176","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2021.06.016","article-title":"Humoral immune response to messenger RNA COVID-19 vaccines among patients with inflammatory bowel disease","volume":"161","author":"Kappelman","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmi.2021.09.036_bib177","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211038111","article-title":"Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab","volume":"14","author":"Capuano","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.cmi.2021.09.036_bib178","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220781","article-title":"SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity","author":"Mrak","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2021.09.036_bib179","article-title":"Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV","author":"Ruddy","year":"2021","journal-title":"AIDS Lond Engl"},{"key":"10.1016\/j.cmi.2021.09.036_bib180","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.anai.2021.07.021","article-title":"Specific antibody response of patients with common variable immunodeficiency to BNT162b2 coronavirus disease 2019 vaccination","volume":"127","author":"Abo-Helo","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.cmi.2021.09.036_bib181","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S2213-2600(21)00220-4","article-title":"BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers","volume":"9","author":"Lustig","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2021.09.036_bib182","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2021.07.042","article-title":"Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan","author":"Kageyama","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2021.09.036_bib183","article-title":"The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data","author":"Chodick","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.09.036_bib184","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2021.05.044","article-title":"Effectiveness of SARS-CoV-2 vaccination in a veterans affairs cohort of inflammatory bowel disease patients with diverse exposure to immunosuppressive medications","volume":"161","author":"Khan","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmi.2021.09.036_bib185","article-title":"Effectiveness of SARS-CoV-2 mRNA vaccines for preventing Covid-19 hospitalizations in the United States","author":"Tenforde","year":"2021","journal-title":"MedRxiv"},{"key":"10.1016\/j.cmi.2021.09.036_bib186","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13705","article-title":"Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients","author":"Aslam","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2021.09.036_bib187","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2021.09.036_bib188","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2021.09.036_bib189","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.cmi.2021.09.036_bib190","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2021.09.036_bib191","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2021.09.036_bib192","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1\u20132a trial of Ad26.COV2.S covid-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2021.09.036_bib193","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.cmi.2021.09.036_bib194","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3851\/IMP2103","article-title":"Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine","volume":"17","author":"Siegrist","year":"2012","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cmi.2021.09.036_bib195","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/irv.12024","article-title":"Influence of renal replacement therapy on immune response after one and two doses of the A(H1N1) pdm09 vaccine","volume":"7","author":"Quintana","year":"2013","journal-title":"Influenza Other Respir Virus."},{"key":"10.1016\/j.cmi.2021.09.036_bib196","doi-asserted-by":"crossref","first-page":"6864","DOI":"10.1016\/j.vaccine.2012.09.005","volume":"30","author":"Lagler","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2021.09.036_bib197","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1080\/21645515.2019.1627160","article-title":"Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia","volume":"15","author":"Lindstr\u00f6m","year":"2019","journal-title":"Hum Vaccine Immunother"},{"key":"10.1016\/j.cmi.2021.09.036_bib198","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.ajkd.2008.11.032","article-title":"Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: an open-label trial","volume":"54","author":"Scharp\u00e9","year":"2009","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"10.1016\/j.cmi.2021.09.036_bib199","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.2215\/CJN.04670511","article-title":"Influenza A\/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study","volume":"6","author":"Broeders","year":"2011","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"10.1016\/j.cmi.2021.09.036_bib200","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4161\/hv.26593","article-title":"Clinical validation of IFN\u03b3\/IL-10 and IFN\u03b3\/IL-2 FluoroSpot assays for the detection of Tr1 T cells and influenza vaccine monitoring in humans","volume":"10","author":"Chauvat","year":"2014","journal-title":"Hum Vaccine Immunother"},{"key":"10.1016\/j.cmi.2021.09.036_bib201","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2021.09.036_bib202","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/21645515.2020.1777822","article-title":"Immunogenicity of H5N1 influenza vaccines in elderly adults: a systematic review and meta-analysis","volume":"17","author":"Zhang","year":"2021","journal-title":"Hum Vaccine Immunother"},{"key":"10.1016\/j.cmi.2021.09.036_bib203","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.vaccine.2005.08.105","article-title":"Antibody response to influenza vaccination in the elderly: a quantitative review","volume":"24","author":"Goodwin","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2021.09.036_bib204","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1016\/j.vaccine.2013.04.085","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2021.09.036_bib205","doi-asserted-by":"crossref","first-page":"9316","DOI":"10.1016\/j.vaccine.2011.10.011","article-title":"Evaluation of hepatitis B vaccine immunogenicity among older adults during an outbreak response in assisted living facilities","volume":"29","author":"Tohme","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2021.09.036_bib206","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s10875-012-9813-x","article-title":"Rituximab-treated patients have a poor response to influenza vaccination","volume":"33","author":"Eisenberg","year":"2013","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.cmi.2021.09.036_bib207","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/acr.22246","article-title":"Effect of methotrexate, anti-tumor necrosis factor \u03b1, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"66","author":"Hua","year":"2014","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.cmi.2021.09.036_bib208","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1182\/blood-2011-08-372649","article-title":"Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment","volume":"118","author":"Yri","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2021.09.036_bib209","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.4161\/hv.29094","article-title":"Immunogenicity of a monovalent influenza A(H1N1)pdm09 vaccine in patients with hematological malignancies","volume":"10","author":"Ide","year":"2014","journal-title":"Hum Vaccine Immunother"},{"key":"10.1016\/j.cmi.2021.09.036_bib210","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000010380","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study","volume":"95","author":"Bar-Or","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.cmi.2021.09.036_bib211","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3899\/jrheum.170710","article-title":"A\u00a0systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis","volume":"45","author":"Subesinghe","year":"2018","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.cmi.2021.09.036_bib212","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1016\/j.vaccine.2020.04.002","article-title":"High dose trivalent influenza vaccine compared to standard dose vaccine in patients with rheumatoid arthritis receiving TNF-alpha inhibitor therapy and healthy controls: results of the DMID 10-0076 randomized clinical trial","volume":"38","author":"Stapleton","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2021.09.036_bib213","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2021.09.036_bib214","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.cmi.2021.09.036_bib215","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1053\/j.ajkd.2021.05.004","article-title":"Clinically significant COVID-19 following SARS-CoV-2 vaccination in kidney transplant recipients","volume":"78","author":"Tsapepas","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cmi.2021.09.036_bib216","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1111\/ajt.16713","article-title":"Effectiveness of SARS-CoV-2 vaccination in fully-vaccinated solid organ transplant recipients","volume":"21","author":"Malinis","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2021.09.036_bib217","first-page":"3233","article-title":"BNT162b2 Messenger RNA COVID-19 vaccine effectiveness in patients with inflammatory bowel disease: preliminary real-world data during mass vaccination campaign","author":"Ben-Tov","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmi.2021.09.036_bib218","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of covid-19 vaccines against the B.1.617.2 (delta) variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2021.09.036_bib219","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.15585\/mmwr.mm7037e1","article-title":"Monitoring incidence of COVID-19 cases, hospitalizations, and deaths, by vaccination status - 13 U.S. Jurisdictions, April 4-July 17, 2021","volume":"70","author":"Scobie","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.cmi.2021.09.036_bib220","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/s41591-021-01435-1","article-title":"A\u00a0French cohort for assessing COVID-19 vaccine responses in specific populations","volume":"27","author":"Loubet","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2021.09.036_bib221","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41591-021-01464-w","article-title":"Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19\/mRNA vaccination","volume":"27","author":"Schmidt","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2021.09.036_bib222","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41591-021-01449-9","article-title":"Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19\/BNT162b2 vaccination","volume":"27","author":"Barros-Martins","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2021.09.036_bib223","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1016\/j.vaccine.2020.04.022","article-title":"Systematic review and meta-analysis of immune response of double dose of hepatitis B vaccination in HIV-infected patients","volume":"38","author":"Lee","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2021.09.036_bib224","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s12664-015-0595-y","article-title":"The efficacy of accelerated, multiple, double-dose hepatitis B vaccine against hepatitis B virus infection in cancer patients receiving chemotherapy","volume":"34","author":"Sodhi","year":"2015","journal-title":"Indian J Gastroenterol Off J Indian Soc Gastroenterol"},{"key":"10.1016\/j.cmi.2021.09.036_bib225","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2020.10245","article-title":"Monoclonal antibodies for prevention and treatment of COVID-19","volume":"324","author":"Marovich","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2021.09.036_bib226","unstructured":"Olivier Epaulard, Jean-Daniel Leli\u00e8vre, Sophie Tchakamian. Strat\u00e9gie de vaccination contre le Sars-Cov-2 - vaccination prioritaire de l'entourage des personnes immunod\u00e9prim\u00e9es contre le SARS-CoV-2. Haute Autorit\u00e9 de Sant\u00e9, 29 April 2021."}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X21005668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X21005668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:31:44Z","timestamp":1761118304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X21005668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":222,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1198743X21005668"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2021.09.036","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2021.09.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}